FDA Recalls All Ameridose Products as Sterility Precaution

FDA concerns over sterility of products prompted a voluntary recall by Westborough, Mass.-based Ameridose of all its unexpired products in circulation, according to the American Society of Anesthesiology.

Advertisement

The FDA is currently conducting an inspection of the facility, and its preliminary findings have raised concerns about sterility assurance for all products produced and distributed by the facility.

The recall was not based on reports of patients with infections from Ameridose products, but rather a precaution since Ameridose shares common management with New England Compounding Center, the firm associated with the compounding drugs linked to the meningitis outbreak.

For a full list of Ameridose products, visit their site.

More Articles on Anesthesia:
Watching Videos Before Anesthesia Induction Reduces Stress in Children
Dicolfenac Provides Significant Pain Relief for Abdominal, Pelvic Surgeries
Can ASCs Still Profit From Anesthesia? A Review of OIG Guidance

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Anesthesia

  • As the shortage of physician anesthesiologists across the U.S. becomes more severe, certified-registered nurse anesthetists have emerged as an essential…

  • As of April 6, 2026, CRNAs’ average annual salary is $276,434, according to salary transparency platform Marit Health’s compilation of…

Advertisement

Comments are closed.